Compounds > nephritogenoside
Page last updated: 2024-12-07

nephritogenoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nephritogenoside: isolated from a variety of tissue types; receptor glycoprotein for concanavalin A from rat glomerular basement membrane [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121932
CHEBI ID175877
MeSH IDM0064584

Synonyms (14)

Synonym
CHEBI:175877
81276-22-4
(2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal
nephritogenoside
nephritogenic glycopeptide
nephritogenic glycoprotein
nephritogenic glycoprotein, mouse
nephritogenoside protein, rat
nephritogenic glycoprotein, human
nephritogenoside protein, human
nephritogenoside protein, mouse
d-glucose, o-alpha-d-glucopyranosyl-(1-6)-o-d-glucopyranosyl-(1-6)-
nephritogenic glycoprotein, rat
(2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}hexanal

Research Excerpts

Overview

Nephritogenoside is a glycopeptide with the ability to induce chronic progressive glomerulonephritis (end stage kidney) in homologous animals, by a single footpad injection.

ExcerptReferenceRelevance
"Nephritogenoside is a minor component of the basement membrane of normal animals (including humans). "( The structure of nephritogenoside.
Ogihara, Y; Sawaki, M; Shibata, S; Takeda, T, 1989)		2.06
"Nephritogenoside is a glycopeptide with the ability to induce chronic progressive glomerulonephritis (end stage kidney) in homologous animals, by a single footpad injection. "( The structure of nephritogenoside. A nephritogenic glycopeptide with alpha-N-glycosidic linkage.
Natori, Y; Shibata, S; Takeda, T, 1988)		2.06

Effects

ExcerptReferenceRelevance
"Nephritogenoside has been prepared by coupling of the acyl azide derivative of a N-triglycosyl dipeptide, derived from the corresponding hydrazide derivative of O-(2,3,4,6-tetra-O-acetyl-alpha-D-glucopyranosyl)-(1-->6)-O-(2,3,4-tri-O -acetyl - beta-D-glucopyranosyl)-(1-->6)-2,3-di-O-benzyl-1-N-[N-(tert-butoxycarbon yl)- L-aspart-1-oyl-(L-proline methyl ester)-4-oyl]-alpha-D-glucopyranosylamine, with a nonadecapeptide, followed by deprotection of the desired protected nephritogenoside. "( Syntheses of nephritogenoside and related compounds.
Kojima, K; Ogihara, Y; Takeda, T, 1993)		2.1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
O-acyl carbohydrateA carbohydrate derivative in which the hydrogen atom of at least one alcoholic hydroxy group of a carbohydrate has been replaced by an acyl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (79.17)18.7374
1990's4 (16.67)18.2507
2000's1 (4.17)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.77 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index3.99 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (20.83%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (79.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
trichloroacetic acid
Trichloroacetic Acid: A strong acid used as a protein precipitant in clinical chemistry and also as a caustic for removing warts.. trichloroacetic acid : A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.		1.9610monocarboxylic acid;
organochlorine compound		carcinogenic agent;
metabolite;
mouse metabolite
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		1.9510D-glucopyranoseepitope;
mouse metabolite
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Genetic Predisposition
[description not available]		02.0110
Glomerulonephritis, Lupus
[description not available]		02.0110
Lupus Nephritis
Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).		02.0110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.2920
Bright Disease
A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.		04.3880
Glomerulonephritis
Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.		09.3880
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.3720
Kahler Disease
[description not available]		01.9610
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		01.9610
Nephritis
Inflammation of any part of the KIDNEY.		09.0430
Extramembranous Glomerulopathy
[description not available]		03.2920
Glomerulonephritis, Membranous
A type of glomerulonephritis that is characterized by the accumulation of immune deposits (COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane.		03.2920
Nephrotic Syndrome
A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.		02.8810
Edema-Proteinuria-Hypertension Gestosis
[description not available]		01.9610
Pre-Eclampsia
A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.		01.9610